Nerivio
Nerivio, a Theranica Bio-Electronics brand, sells FDA-cleared prescription Remote Electrical Neuromodulation wearables for acute and preventive migraine treatment in patients aged 8 and older, distributed via healthcare providers, telemedicine, the VA, and international channels across 8 countries.
- Company typePrivate
- Founded2019
- HeadquartersBridgewater, United States
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What Nerivio does
Nerivio is a prescription medical device brand operated by Theranica Bio-Electronics Ltd., an Israeli medical device company with US operations through Theranica USA Inc., headquartered in Bridgewater, New Jersey. The company develops and markets the Nerivio family of Remote Electrical Neuromodulation (REN) wearables for acute and preventive migraine treatment in patients aged 8 and older. It serves a horizontal segmentation of migraine sufferers—children, adolescents, adults, veterans, women of childbearing age, patients with comorbidities, and individuals in safety-sensitive occupations—through prescription-only channels that include traditional healthcare providers, a telemedicine partner, a dedicated Veterans Affairs pathway, and international distributors across 8 countries (US, UK, India, Germany, Spain, South Africa, Israel, HK/China).
The core technology is a wearable device applied to the upper arm that delivers electrical stimulation to Aδ and C nerve fibers at 100–120 Hz and 400 μS pulse width, activating the brain's Conditioned Pain Modulation system and triggering descending pain inhibitory pathways that release serotonin and norepinephrine—a mechanism distinct from TENS units that rely on gate-theory pain modulation. The device is controlled via the Nerivio smartphone app (iOS 16+ and Android 11+), which provides machine-learning-driven 24-hour migraine likelihood predictions, treatment tracking, NFC authentication of electrode pads, and Guided Imagery, Education, and Relaxation (GIER) behavioral therapy developed by headache psychologists. Two hardware SKUs are offered: a disposable Nerivio unit providing 18 treatments and a rechargeable Nerivio Infinity model with replaceable electrode pads.
Nerivio operates a prescription hardware-sales model with refill-based revenue mechanics. Retail pricing is up to $1,598 per 18-treatment refill, with a Nerivio Savings Program capping co-insurance at $89 per refill for eligible commercially insured patients; Medicaid and commercial insurance coverage are explicitly supported. Pharmacy fulfillment is handled by ProCare Rx, and the clinical evidence base includes 9 pivotal studies, 25+ peer-reviewed publications, and real-world data from 1.8M+ treatments across 15,000+ patients. FDA clearances include the original De Novo (DEN180059, May 2019), a preventive-treatment clearance (2023), and the expanded pediatric/adolescent indication (K241756, October 2025). The company is privately held with no disclosed funding rounds or external investor information.
Nerivio firmographics
Firmographics- Name
- Nerivio
- Legal name
- Theranica Bio-Electronics Ltd.
- Website
- https://nerivio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Nerivio, a Theranica Bio-Electronics brand, sells FDA-cleared prescription Remote Electrical Neuromodulation wearables for acute and preventive migraine treatment in patients aged 8 and older, distributed via healthcare providers, telemedicine, the VA, and international channels across 8 countries.
- Ownership category
- akta.pro rank
Nerivio industry classification
Industry- Product category
- Migraine Treatment Device
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
- akta.pro secondary industry
- Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)
Keywords
Where Nerivio is headquartered
LocationHeadquarters
- HQ city
- Bridgewater
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nerivio business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
Revenue model
- Device Sales - Nerivio: Prescription-based one-time device purchase model. Nerivio disposable device provides 18 treatments. Starter sets include reusable hardware (armband, charger) plus refill units. Retail price up to $1,598 for 18 treatments.
- Refill/Replacement Units: Disposable Nerivio devices and Nerivio Infinity electrode pads (18 treatments each) are replaced as consumables through pharmacy fulfillment. Nerivio is prescribed therapy—not a subscription.
- Nerivio Savings Program: Patient assistance program with co-insurance capped at $89 per refill for eligible commercially insured patients, not available to Medicare, Medicaid, TRICARE or other government healthcare program patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Nerivio Starter Set - First prescription order |
| One time/ perpetual license | Pay-as-you-go | Nerivio Refill Unit - Replacement device (18 treatments) |
| Other | Pay-as-you-go | Nerivio Savings Program - Co-pay assistance |
Distribution channels5 records
Marketing channels7 records
Nerivio product offering
Product offeringCore offering
Nerivio is a prescription-only Remote Electrical Neuromodulation (REN) wearable device that delivers 45-minute drug-free neurostimulation sessions to the upper arm to prevent and treat migraine in patients ages 8 and older. The product line includes the disposable Nerivio (18 treatments per device) and the rechargeable Nerivio Infinity (replaceable electrode pads with 18 treatments each), both controlled via the Nerivio smartphone app. Devices are prescribed by healthcare providers or through a telemedicine partner, fulfilled by pharmacy partner ProCare Rx, and paid for via insurance (commercial and Medicaid) or the Nerivio Savings Program.
Product overview
Nerivio is a prescription medical device company offering the Nerivio REN (Remote Electrical Neuromodulation) wearable family for drug-free migraine treatment and prevention in patients 8 years and older. The product portfolio consists of two wearable models—Nerivio (disposable, 18 treatments) and Nerivio Infinity (rechargeable with replaceable electrode pads)—both controlled via the Nerivio smartphone app. The app serves as the central platform for treatment management, migraine tracking, ML-powered predictive analytics for 24-hour migraine likelihood, treatment reminders, and access to GIER (Guided Imagery, Education, and Relaxation) behavioral therapy content. Nerivio is prescribed for acute treatment at migraine onset and/or preventive treatment every other day, offering dual-use therapy without systemic side effects.
Differentiator
Problem solved
Functional benefit
Products and services
- Nerivio (disposable wearable) A prescription-required, single-use Remote Electrical Neuromodulation (REN) wearable device providing 18 treatments of 45 minutes each, controlled via the Nerivio smartphone app, indicated for acute and preventive migraine treatment in patients ages 8 and older.
- Nerivio Infinity (rechargeable wearable) A rechargeable, durable Remote Electrical Neuromodulation (REN) wearable with replaceable electrode pads (each providing 18 treatments), managed through the Nerivio app with NFC authentication for electrode pairing, indicated for acute and preventive migraine treatment in patients ages 8 and older.
Quantifiable outcome
- 66.7% of patients achieved pain relief at 2 hours post-treatment (Yarnitsky et al. 2019)
- +9 more outcomes
Companies that use Nerivio
Customer profileNamed customers8 records
Segments7 records
Ideal customer profiles4 records
Nerivio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
Nerivio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ProCare RxcorePrimary pharmacy fulfillment partner for Nerivio prescriptions. After healthcare provider prescribes Nerivio, ProCare Rx contacts patients for insurance and payment information and delivers devices directly to patient doorstep. Handles both initial prescriptions and refills.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Nerivio competitors and assessment
Company assessmentDirect peers
- gammaCore (electroCore): gammaCore is a non-invasive vagus nerve stimulation (nVNS) device FDA-cleared for migraine and cluster headache; it is the closest analog to Nerivio in the prescription neuromodulation migraine category with overlapping prescribers and payer positioning.
- eNeura (SpringTMS): eNeura's SpringTMS is a single-pulse transcranial magnetic stimulation device FDA-cleared for acute and preventive migraine, making it a direct neuromodulation peer to Nerivio within the prescription, non-pharmacologic migraine category.
- Relivion (Neurolief): Relivion is an external, multi-channel trigeminal and occipital nerve stimulation headset for acute migraine, directly competing with Nerivio's non-invasive, app-controlled neurostimulation approach for the same patient population.
- Cefaly: Cefaly is a direct competitor offering an external TENS-based trigeminal nerve stimulation device (Cefaly Connected) for migraine prevention and acute treatment, overlapping with Nerivio on indication, prescription channel, and patient demographic.
Broad incumbents
- AbbVie (Botox, Ubrelvy): AbbVie markets Botox for chronic migraine and Ubrelvy (ubrogepant) for acute migraine, providing both preventive and acute pharmacologic alternatives that compete with Nerivio's drug-free positioning across the migraine treatment continuum.
- Lundbeck (Vyepti): Lundbeck's Vyepti (eptinezumab) is an IV-administered CGRP monoclonal antibody for migraine prevention, a larger-pharma preventive option that competes for the same specialty neurology prescribing channel Nerivio targets.
- Teva Pharmaceutical (Ajovy): Teva markets Ajovy (fremanezumab), a CGRP monoclonal antibody for migraine prevention, representing another injectable preventive pharmacologic option that competes with Nerivio's non-pharmacologic preventive claim.
- Pfizer (Nurtec ODT): Pfizer markets Nurtec ODT, a leading oral CGRP receptor antagonist gepant for acute and preventive migraine; it competes with Nerivio for the same prescriber and patient mindshare within broader migraine therapy.
- Eli Lilly (Emgality, Reyvow): Eli Lilly markets Emgality (galcanezumab), a CGRP monoclonal antibody for migraine prevention, and Reyvow (lasmiditan), an acute serotonin receptor agonist, both directly competitive alternatives to Nerivio within migraine management.
Emerging players
- Salvia Bioelectronics: Salvia is an early-stage Dutch neurostim developer working on a thin, foil-like active implantable device targeting chronic headache disorders, including cluster headache; relevant as a forward-looking neurostimulation peer entering Nerivio's broader headache adjacency.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Nerivio social profiles
Digital presenceNerivio compliance and trust
Trust signalCompliance3 records
Nerivio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nerivio leadership team
Management profileNumber of profiles
Nerivio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nerivio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nerivio
What does Nerivio do?
Nerivio is a prescription-only Remote Electrical Neuromodulation (REN) wearable device that delivers 45-minute drug-free neurostimulation sessions to the upper arm to prevent and treat migraine in patients ages 8 and older. The product line includes the disposable Nerivio (18 treatments per device) and the rechargeable Nerivio Infinity (replaceable electrode pads with 18 treatments each), both controlled via the Nerivio smartphone app. Devices are prescribed by healthcare providers or through a telemedicine partner, fulfilled by pharmacy partner ProCare Rx, and paid for via insurance (commercial and Medicaid) or the Nerivio Savings Program.
Is Nerivio a public or private company?
Nerivio is a private company. It is classified as unknown and is currently operating.
When was Nerivio founded?
Nerivio was founded in 2019. It employs 51 to 100 people.
Where is Nerivio based?
Nerivio is headquartered in Bridgewater, United States, in the North America region.
How does Nerivio make money?
Three revenue lines are on record. Device Sales - Nerivio is the primary driver. The others are refill/Replacement Units and nerivio Savings Program.
Who are Nerivio's main competitors?
Direct peers on record are gammaCore (electroCore), eNeura (SpringTMS), Relivion (Neurolief) and Cefaly. Broad incumbents are AbbVie (Botox, Ubrelvy), Lundbeck (Vyepti), Teva Pharmaceutical (Ajovy), Pfizer (Nurtec ODT) and Eli Lilly (Emgality, Reyvow). Salvia Bioelectronics is listed as an emerging player.
Does Nerivio have an API?
No public API is recorded for Nerivio.
What industry is Nerivio in?
Nerivio's product category is Migraine Treatment Device. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of HLACANAJ, Digital Rehabilitation & Physical Therapy Therapeutics. Its NAICS code is 334510 and its SIC code is 3845.